Their late-stage reveal on selonsertib — along with a similar unveiling from Intercept — is one of the most anticipated events of the year. And Gilead has two other mid-stage drugs in the pipeline to help build what it hopes will be an industry-leading cocktail for NASH, much like they did for HIV and hepatitis C. Those 3 clinical drugs make up half of the 6 drugs Gilead lists in its pipeline for liver diseases, including hepatitis B.
On Sunday, the eve of the JP Morgan confab, Gilead added a new discovery program in NASH-related fibrosis with South Korea’s Yuhan Corporation — which handles commercialization work on Gilead’s drugs in the Asian country.
There aren’t a lot of details in the statement about what they’ll be going after, other than 2 unspecified targets, but Gilead seeded the deal with a $15 million upfront and a mother lode of milestones that tot up to $770 million.
This deal follows closely on a new alliance Gilead struck with Scholar Rock that came with $105 million in quick cash in exchange for a shot at 3 programs: Inhibitors targeting activation of latent TGFβ1, inhibitors targeting activation of latent TGFβ1 localized to the extracellular matrix, and a third TGFβ program.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription